Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN728 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dose 1 versus placebo |
| Cohort 2 | EXPERIMENTAL | Dose 2 versus placebo |
| Name | Type | Description |
|---|---|---|
| REGN728 | BIOLOGICAL | 2 Subcutaneous Cohorts (dose 1, 2) |
Inclusion Criteria: * Male or female 18 to 65 years of age. * Weight\> 50 kg and \<95 kg inclusive * For men of childbearing potential, willingness to utilize adequate contraception and not have their partner\[s\] become pregnant during the full duration of the study. * Willing, committed, and able...
REGN728 is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. Regeneron has not publicly disclosed the specific disease indications being pursued for this asset, so its intended therapeutic use remains undisclosed.
REGN728 targets angiopoietin-2, also known as ANG2, a protein. Angiopoietin-2 is a signaling protein involved in vascular biology, and REGN728 is a monoclonal antibody designed to bind it. The target class is a protein, and the antibody modality is intended to modulate ANG2 activity.
REGN728 is developed by Regeneron Pharmaceuticals, Inc., which trades on Nasdaq under the ticker REGN. Regeneron is the sponsor of the clinical program for this monoclonal antibody. The company has not disclosed the specific disease indications it intends to pursue with REGN728.
REGN728 is in Phase 1 development. It is an investigational monoclonal antibody and has not been approved by the FDA. The only recorded trial, NCT01197391, is a completed Phase 1 study, and no active trials are currently listed for this asset.
REGN728 has been studied in one clinical trial, NCT01197391, titled "Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers." This completed Phase 1 trial enrolled 48 healthy adult volunteers in the United States and used a randomized, double-blind, controlled design.